US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
EP1569661B1
(en)
|
2002-11-18 |
2009-09-09 |
Santaris Pharma A/S |
Antisense design
|
US20050287558A1
(en)
|
2004-05-05 |
2005-12-29 |
Crooke Rosanne M |
SNPs of apolipoprotein B and modulation of their expression
|
DE102005042073B4
(de)
*
|
2005-08-31 |
2010-11-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Faserlaser
|
CN103301475B
(zh)
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
PL2314594T3
(pl)
*
|
2006-01-27 |
2014-12-31 |
Isis Pharmaceuticals Inc |
Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
|
WO2007134014A2
(en)
|
2006-05-05 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of gcgr
|
EP2505649A1
(en)
*
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of GCGR
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
DK2066684T3
(da)
*
|
2006-05-11 |
2012-10-22 |
Isis Pharmaceuticals Inc |
5´-Modificerede bicycliske nukleinsyreanaloge
|
ES2620472T5
(es)
|
2006-10-18 |
2020-07-09 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
EP2102340A2
(en)
*
|
2006-11-27 |
2009-09-23 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
KR20150090284A
(ko)
|
2007-03-24 |
2015-08-05 |
젠자임 코포레이션 |
인간 아포리포프로틴 b에 상보적인 안티센스 올리고뉴클레오타이드 투여
|
ES2376507T5
(es)
*
|
2007-07-05 |
2015-08-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos 6-disustituidos
|
ES2439591T3
(es)
|
2007-08-15 |
2014-01-23 |
Isis Pharmaceuticals, Inc. |
Análogos de ácido nucleico de tetrahidropirano
|
US20110059895A1
(en)
|
2007-11-09 |
2011-03-10 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 9 expression
|
EP2227545A2
(en)
|
2007-11-09 |
2010-09-15 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 7 expression
|
US8530640B2
(en)
*
|
2008-02-07 |
2013-09-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
EP2282744B1
(en)
*
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
WO2009124238A1
(en)
*
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
WO2009143387A2
(en)
*
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Modulation of smrt expression
|
WO2010017509A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
WO2010019270A1
(en)
*
|
2008-08-14 |
2010-02-18 |
Isis Pharmaceuticals, Inc. |
Modulation of prion expression
|
US8946172B2
(en)
*
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
CN103429270B
(zh)
|
2008-08-25 |
2016-11-23 |
埃克斯雷德制药有限公司 |
阻止结缔组织生长因子的反义核苷酸及其用途
|
EP2334319B1
(en)
|
2008-08-25 |
2017-12-06 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
EP2356129B1
(en)
*
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
CA2739464C
(en)
|
2008-10-03 |
2020-03-31 |
Opko Curna, Llc |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
NZ592203A
(en)
|
2008-10-15 |
2013-01-25 |
Isis Pharmaceuticals Inc |
Modulation of factor 11 expression
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
CA2744987C
(en)
|
2008-12-02 |
2018-01-16 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
MX2011005910A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
|
CA2746003C
(en)
|
2008-12-04 |
2020-03-31 |
Opko Curna, Llc |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
US20110294870A1
(en)
|
2008-12-04 |
2011-12-01 |
Opko Curna, Llc |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
WO2010076248A1
(en)
|
2008-12-31 |
2010-07-08 |
Santaris Pharma A/S |
Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
|
WO2010090830A1
(en)
*
|
2009-01-20 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Modulation of sirt1 expression
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
KR101682735B1
(ko)
|
2009-02-12 |
2016-12-06 |
큐알엔에이, 인크. |
뇌 유래된 신경영양성 인자 (bdnf)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (bdnf) 관련된 질환의 치료
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
EP2408796B1
(en)
|
2009-03-16 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
WO2010120511A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Method of treating respiratory disorders
|
CA2761142C
(en)
|
2009-05-06 |
2021-06-08 |
Opko Curna, Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
KR101835889B1
(ko)
|
2009-05-06 |
2018-03-08 |
큐알엔에이, 인크. |
지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료
|
US9012139B2
(en)
|
2009-05-08 |
2015-04-21 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
CN103221541B
(zh)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
|
NZ596608A
(en)
|
2009-06-12 |
2014-01-31 |
Santaris Pharma As |
New potent anti apob antisense compounds
|
ES2629339T3
(es)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
EP3305302B1
(en)
|
2009-06-17 |
2018-09-19 |
Biogen MA Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
JPWO2010150789A1
(ja)
|
2009-06-23 |
2012-12-10 |
武田薬品工業株式会社 |
核酸の合成法
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
KR101807324B1
(ko)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
|
BR112012000828A8
(pt)
|
2009-07-06 |
2017-10-10 |
Ontorii Inc |
Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
CA2768947C
(en)
|
2009-07-24 |
2018-06-19 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
WO2011017516A2
(en)
|
2009-08-05 |
2011-02-10 |
Curna, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
US9012421B2
(en)
|
2009-08-06 |
2015-04-21 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
EP2464731B1
(en)
|
2009-08-11 |
2016-10-05 |
CuRNA, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
EP2982755B1
(en)
|
2009-08-21 |
2020-10-07 |
CuRNA, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
EP2470657B1
(en)
|
2009-08-25 |
2019-10-23 |
CuRNA, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
HUE033113T2
(en)
|
2009-09-11 |
2017-11-28 |
Ionis Pharmaceuticals Inc |
Modifying Huntingtin expression
|
DK2480669T3
(en)
|
2009-09-25 |
2018-02-12 |
Curna Inc |
TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
|
EP2490699A1
(en)
|
2009-10-20 |
2012-08-29 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
WO2011054811A1
(en)
|
2009-11-03 |
2011-05-12 |
Santaris Pharma A/S |
Rna antagonists targeting hsp27 combination therapy
|
CA2782366A1
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
RU2611186C2
(ru)
|
2009-12-29 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
|
EP2519633B1
(en)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
RU2016115782A
(ru)
|
2009-12-31 |
2018-11-28 |
Курна, Инк. |
Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
AU2011203986C1
(en)
|
2010-01-08 |
2015-03-05 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2524039B1
(en)
|
2010-01-11 |
2017-11-29 |
CuRNA, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
WO2011088148A1
(en)
*
|
2010-01-12 |
2011-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of transforming growth factor-beta 1 expression
|
RU2611192C2
(ru)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
|
US8957040B2
(en)
|
2010-02-08 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
EP3208347B1
(en)
|
2010-02-08 |
2019-08-14 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
KR101838308B1
(ko)
|
2010-02-22 |
2018-03-13 |
큐알엔에이, 인크. |
피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료
|
WO2011106689A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Isis Pharmaceuticals, Inc. |
Modulation of smad3 expression
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US8980856B2
(en)
|
2010-04-02 |
2015-03-17 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
|
RU2610661C2
(ru)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
|
CN103154014B
(zh)
|
2010-04-28 |
2015-03-25 |
Isis制药公司 |
修饰核苷、其类似物以及由它们制备的寡聚化合物
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
US9127033B2
(en)
|
2010-04-28 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
5′ modified nucleosides and oligomeric compounds prepared therefrom
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
RS56011B1
(sr)
|
2010-04-29 |
2017-09-29 |
Ionis Pharmaceuticals Inc |
Modulacija ekspresije transtiretina
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
JP5917497B2
(ja)
|
2010-05-26 |
2016-05-18 |
カッパーアールエヌエー,インコーポレイテッド |
メチオニンスルホキシドレダクターゼa(msra)に対する天然アンチセンス転写物の阻害によるmsra関連疾患の治療
|
EP2576783B1
(en)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
US9944671B2
(en)
|
2010-06-02 |
2018-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011156202A1
(en)
|
2010-06-08 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2582397A4
(en)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR MODULATING THE INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
|
JP6023705B2
(ja)
|
2010-06-23 |
2016-11-09 |
カッパーアールエヌエー,インコーポレイテッド |
ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療
|
WO2012007477A1
(en)
|
2010-07-12 |
2012-01-19 |
Santaris Pharma A/S |
Anti hcv oligomers
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
EP3633038A3
(en)
|
2010-07-19 |
2020-07-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
EP2601611B1
(en)
|
2010-08-02 |
2020-12-09 |
Integrated Dna Technologies, Inc. |
Methods for predicting stability and melting temperatures of nucleic acid duplexes
|
WO2012034942A1
(en)
|
2010-09-13 |
2012-03-22 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase b expression
|
US10428019B2
(en)
|
2010-09-24 |
2019-10-01 |
Wave Life Sciences Ltd. |
Chiral auxiliaries
|
ES2640755T3
(es)
|
2010-10-06 |
2017-11-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
EP2630241B1
(en)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
WO2012064758A2
(en)
|
2010-11-08 |
2012-05-18 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
EP3521451A1
(en)
|
2010-11-17 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
WO2012066093A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
WO2012066092A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase a expression
|
US8987225B2
(en)
|
2010-11-23 |
2015-03-24 |
Curna, Inc. |
Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
CA2825059A1
(en)
|
2011-02-02 |
2012-08-09 |
Excaliard Pharmaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012110457A2
(en)
|
2011-02-14 |
2012-08-23 |
Santaris Pharma A/S |
Compounds for the modulation of osteopontin expression
|
RU2702501C2
(ru)
|
2011-03-29 |
2019-10-08 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии гена tmprss6
|
HUE042173T2
(hu)
|
2011-04-01 |
2019-06-28 |
Ionis Pharmaceuticals Inc |
'Signal transducer and activator of transcription 3' (stat3) expresszió modulálása
|
CA2832972C
(en)
|
2011-04-13 |
2019-04-30 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
WO2012143427A1
(en)
|
2011-04-19 |
2012-10-26 |
Santaris Pharma A/S |
Anti polyomavirus compounds
|
RU2667524C2
(ru)
|
2011-04-21 |
2018-09-21 |
Ионис Фармасьютикалз, Инк. |
Модулирование экспрессии вируса гепатита b (hbv)
|
HUE031595T2
(en)
|
2011-04-25 |
2017-07-28 |
Regulus Therapeutics Inc |
Micro RNA Compounds s Methods for Modulating Mir-21 Activity
|
DK3357497T3
(en)
|
2011-04-27 |
2020-11-23 |
Ionis Pharmaceuticals Inc |
Modulation af apolipoprotein ciii (apociii) ekspression
|
US9353371B2
(en)
|
2011-05-02 |
2016-05-31 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
ES2653247T3
(es)
|
2011-06-09 |
2018-02-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
|
EP3320922A1
(en)
|
2011-06-10 |
2018-05-16 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
US9187749B2
(en)
|
2011-06-10 |
2015-11-17 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
CN103597074A
(zh)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
成纤维细胞生长因子受体4表达的反义调节
|
AU2012272970A1
(en)
|
2011-06-21 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
EP2723863A1
(en)
|
2011-06-23 |
2014-04-30 |
Stella ApS |
Hcv combination therapy
|
US9322021B2
(en)
|
2011-06-29 |
2016-04-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
KR20140064765A
(ko)
|
2011-06-30 |
2014-05-28 |
스텔라 에이피에스 |
Hcv 조합 치료
|
KR20140058536A
(ko)
|
2011-06-30 |
2014-05-14 |
스텔라 에이피에스 |
Hcv 조합 치료
|
RU2014105311A
(ru)
|
2011-07-19 |
2015-08-27 |
Уэйв Лайф Сайенсес Пте. Лтд. |
Способы синтеза функционализованных нуклеиновых кислот
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
WO2013022967A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
CN108272782B
(zh)
|
2011-09-06 |
2021-04-23 |
库尔纳公司 |
小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途
|
WO2013040429A1
(en)
|
2011-09-14 |
2013-03-21 |
Rana Therapeutics Inc. |
Multimeric oligonucleotide compounds
|
ES2673721T3
(es)
|
2011-09-20 |
2018-06-25 |
Ionis Pharmaceuticals, Inc. |
Modulación antisentido de la expresión de GCGR
|
WO2013063313A1
(en)
|
2011-10-25 |
2013-05-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
WO2013067050A1
(en)
|
2011-10-31 |
2013-05-10 |
University Of Utah Research Foundation |
Genetic alterations in glioblastoma
|
CA2853328A1
(en)
|
2011-11-07 |
2013-05-16 |
Stella Aps |
Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
|
WO2013068348A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Lna oligomers for improvement in hepatic function
|
ES2761343T3
(es)
|
2011-11-07 |
2020-05-19 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de TMPRSS6
|
EA201400566A1
(ru)
|
2011-11-11 |
2014-09-30 |
Сэнтерис Фарма А/С |
Соединения, предназначенные для модуляции сплайсинга smn2
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
CA2895077A1
(en)
|
2011-12-12 |
2013-06-20 |
Beverly Packard |
In vivo delivery of oligonucleotides
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
EP2794880B1
(en)
|
2011-12-22 |
2018-05-02 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
|
EP2802674B1
(en)
|
2012-01-11 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of ikbkap splicing
|
WO2013119602A1
(en)
|
2012-02-06 |
2013-08-15 |
President And Fellows Of Harvard College |
Arrdc1-mediated microvesicles (armms) and uses thereof
|
EP3330278A1
(en)
|
2012-02-08 |
2018-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US9340784B2
(en)
|
2012-03-19 |
2016-05-17 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
EP2831231A1
(en)
|
2012-03-30 |
2015-02-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
WO2013154798A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
EP2839006B1
(en)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
KR20230037703A
(ko)
|
2012-04-25 |
2023-03-16 |
사노피 |
마이크로rna 화합물 및 mir-21 활성 조절 방법
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
DK2850189T3
(en)
|
2012-05-16 |
2019-02-25 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING GENEPRESSION
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Smn遺伝子ファミリー発現を調節するための組成物及び方法
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
EP2852606B1
(en)
|
2012-05-22 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation of enhancer rna mediated gene expression
|
LT2855500T
(lt)
|
2012-05-24 |
2020-11-10 |
Ionis Pharmaceuticals, Inc. |
Būdai ir kompozicijos, skirti apolipoproteino (a) raiškos moduliacijai
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
JP6294876B2
(ja)
|
2012-06-25 |
2018-03-14 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Ube3a−ats発現の調節
|
JP6268157B2
(ja)
|
2012-07-13 |
2018-01-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
MX356830B
(es)
|
2012-07-13 |
2018-06-15 |
Shin Nippon Biomedical Laboratories Ltd |
Adyuvante de acido nucleico quiral.
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
US20150297629A1
(en)
|
2012-07-27 |
2015-10-22 |
Isis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
CN104736551B
(zh)
|
2012-08-15 |
2017-07-28 |
Ionis制药公司 |
使用改进的封端方案制备寡聚化合物的方法
|
EP2906225B1
(en)
|
2012-10-11 |
2021-12-22 |
Ionis Pharmaceuticals, Inc. |
A modified antisense compound for use in treating kennedy's disease
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
WO2014059341A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
US20150275208A1
(en)
|
2012-10-12 |
2015-10-01 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
JP6570447B2
(ja)
|
2012-10-15 |
2019-09-04 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
C9orf72発現を調節するための組成物
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
US9963699B2
(en)
|
2012-10-15 |
2018-05-08 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating C9ORF72 expression
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
EP3483273A1
(en)
|
2012-10-31 |
2019-05-15 |
Ionis Pharmaceuticals, Inc. |
Cancer treatment
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
MY173826A
(en)
|
2012-11-15 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
Oligonucleotide conjugates
|
WO2014080004A1
(en)
|
2012-11-26 |
2014-05-30 |
Santaris Pharma A/S |
Compositions and methods for modulation of fgfr3 expression
|
EP4074834A1
(en)
|
2012-11-26 |
2022-10-19 |
ModernaTX, Inc. |
Terminally modified rna
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
WO2014112463A1
(ja)
*
|
2013-01-15 |
2014-07-24 |
国立大学法人大阪大学 |
スルホンアミド構造を有するヌクレオシドおよびヌクレオチド
|
EP2946014A2
(en)
|
2013-01-17 |
2015-11-25 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
EP2945652B1
(en)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
BR112015018161A2
(pt)
|
2013-01-30 |
2017-08-22 |
Hoffmann La Roche |
Conjugado de oligômeros antisense de lna, composição farmacêutica e uso de um conjugado de oligômeros antisense de lna
|
WO2014120861A2
(en)
|
2013-01-31 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
EP3778618A1
(en)
|
2013-02-04 |
2021-02-17 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
ES2961686T3
(es)
|
2013-02-14 |
2024-03-13 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de apolipoproteína C-III (APOCIII) en poblaciones deficientes en lipoproteína lipasa (LPLD)
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
WO2014143158A1
(en)
|
2013-03-13 |
2014-09-18 |
The Broad Institute, Inc. |
Compositions and methods for labeling of agents
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
MX359337B
(es)
|
2013-03-14 |
2018-07-09 |
Andes Biotechnologies Global Inc |
Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
|
BR112015022156A2
(pt)
|
2013-03-14 |
2017-11-14 |
Isis Pharmaceuticals Inc |
composições e métodos para modular a expressão de tau
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
JP2016519083A
(ja)
|
2013-03-14 |
2016-06-30 |
アンデス バイオテクノロジーズ ソシエダード アノニマAndes Biotechnologies S.A. |
多発性骨髄腫を検出および処置するための方法
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
JP2016518842A
(ja)
|
2013-05-01 |
2016-06-30 |
レグルス セラピューティクス インコーポレイテッド |
マイクロRNA化合物およびmiR−122をモジュレートする方法
|
WO2014179445A1
(en)
|
2013-05-01 |
2014-11-06 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
IL284593B2
(en)
|
2013-05-01 |
2023-02-01 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulation of hbv and ttr expression
|
SG11201510565TA
(en)
|
2013-05-22 |
2016-01-28 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
KR102463973B1
(ko)
|
2013-05-22 |
2022-11-07 |
알닐람 파마슈티칼스 인코포레이티드 |
SERPINA1 iRNA 조성물 및 이의 사용 방법
|
KR20160013110A
(ko)
|
2013-05-24 |
2016-02-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
B-세포 cll/림프종 11a(bcl11a)의 올리고뉴클레오티드 조절제 및 이의 용도
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
JP6694382B2
(ja)
|
2013-06-21 |
2020-05-13 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
標的核酸を調節するための組成物および方法
|
US9909124B2
(en)
|
2013-06-21 |
2018-03-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
|
CN112263682A
(zh)
|
2013-06-27 |
2021-01-26 |
罗氏创新中心哥本哈根有限公司 |
靶向pcsk9的反义寡聚体和缀合物
|
CN105452461B
(zh)
|
2013-07-02 |
2021-04-13 |
Ionis制药公司 |
生长激素受体的调节剂
|
HRP20211563T1
(hr)
|
2013-07-11 |
2022-01-07 |
Modernatx, Inc. |
Pripravci koji sadrže sintetske polinukleotide koji kodiraju proteine srodne crispr-u i sintetske sgrna, te postupci njihove uporabe
|
WO2015009731A2
(en)
|
2013-07-15 |
2015-01-22 |
The Regents Of The University Of California |
Azacyclic constrained analogs of fty720
|
TWI657819B
(zh)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
WO2015017675A2
(en)
|
2013-07-31 |
2015-02-05 |
Isis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
EA202191796A2
(ru)
|
2013-08-08 |
2022-03-31 |
Дзе Скриппс Рисёч Инститьют |
Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
JP6652922B2
(ja)
|
2013-08-28 |
2020-02-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
プレカリクレイン(pkk)発現の調節
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN105744959B
(zh)
|
2013-09-13 |
2020-12-01 |
Ionis制药公司 |
补体因子b的调节剂
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
US10077444B2
(en)
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
PE20161130A1
(es)
|
2013-10-04 |
2016-11-25 |
Icahn School Med Mount Sinai |
Composiciones y metodos para inhibir la expresion del gen alas1
|
AU2014331652B2
(en)
|
2013-10-11 |
2020-05-21 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating C9ORF72 expression
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
CN105899679A
(zh)
|
2013-10-21 |
2016-08-24 |
通用医疗公司 |
与循环肿瘤细胞簇有关的方法以及癌症的治疗
|
US9758546B2
(en)
|
2013-10-21 |
2017-09-12 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
WO2015061536A1
(en)
|
2013-10-25 |
2015-04-30 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-21 activity
|
US10752940B2
(en)
|
2013-11-08 |
2020-08-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
US20170268000A1
(en)
|
2013-12-02 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complementary component irna compositions and methods for using them
|
EP3082840B1
(en)
|
2013-12-20 |
2021-03-24 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
WO2015100394A1
(en)
|
2013-12-24 |
2015-07-02 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
CN113057959A
(zh)
|
2014-02-11 |
2021-07-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
JP6902869B2
(ja)
|
2014-03-19 |
2021-07-14 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
アタキシン2の発現を調節するための組成物
|
SG11201608109TA
(en)
|
2014-04-01 |
2016-10-28 |
Ionis Pharmaceuticals Inc |
Compositions for modulating sod-1 expression
|
US10513706B2
(en)
|
2014-04-09 |
2019-12-24 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
EP3797780B1
(en)
|
2014-04-17 |
2022-09-14 |
Biogen MA Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
US9926556B2
(en)
|
2014-04-28 |
2018-03-27 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
EP4223315A3
(en)
|
2014-05-01 |
2023-08-23 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
EP3137605B1
(en)
|
2014-05-01 |
2020-10-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
BR112016022593B1
(pt)
|
2014-05-01 |
2022-04-26 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, composições que os compreendem, e usos dos mesmos
|
RU2724527C2
(ru)
|
2014-05-01 |
2020-06-23 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы модулирования экспрессии рецептора гормона роста
|
CA2943705A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating pkk expression
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
JP6811094B2
(ja)
|
2014-05-22 |
2021-01-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アンジオテンシノーゲン(AGT)iRNA組成物およびその使用
|
EP3148564B1
(en)
|
2014-06-02 |
2020-01-08 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
USD766120S1
(en)
|
2014-06-09 |
2016-09-13 |
Gambro Lundia Ab |
Status light bar
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
MX2017001493A
(es)
|
2014-08-07 |
2017-05-09 |
Regulus Therapeutics Inc |
Eleccion de micro acidos ribonucleicos (arn) como diana para trastornos metabolicos.
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
CN107106704A
(zh)
|
2014-08-29 |
2017-08-29 |
儿童医疗中心有限公司 |
用于治疗癌症的方法和组合物
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
KR102620328B1
(ko)
|
2014-10-03 |
2024-01-02 |
콜드스프링하버러보러토리 |
핵 유전자 산출량의 표적화 증강
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
AU2015329974B2
(en)
|
2014-10-10 |
2019-06-20 |
F. Hoffmann-La Roche Ag |
GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016077540A1
(en)
|
2014-11-12 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of comp
|
US10364433B2
(en)
|
2014-11-14 |
2019-07-30 |
The Regents Of The University Of California |
Modulation of AGPAT5 expression
|
EP3020813A1
(en)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-oligonucleotides as inhibitors of TGF-R signaling
|
EP3221451A1
(en)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016086104A1
(en)
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
AU2015360794B2
(en)
|
2014-12-08 |
2021-07-08 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
JP6689279B2
(ja)
|
2014-12-16 |
2020-05-20 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラル毒性のスクリーニング方法
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
RU2017127609A
(ru)
|
2015-02-04 |
2019-03-04 |
Ф. Хоффманн-Ля Рош Аг |
Антисмысловые олигомеры тау-белка и их применение
|
EP3254104B1
(en)
|
2015-02-04 |
2021-08-25 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
EP3256591A4
(en)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
EP3256587A2
(en)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
NZ733844A
(en)
|
2015-02-26 |
2022-07-01 |
Ionis Pharmaceuticals Inc |
Allele specific modulators of p23h rhodopsin
|
WO2016141236A1
(en)
|
2015-03-03 |
2016-09-09 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
ES2909308T3
(es)
|
2015-03-03 |
2022-05-06 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de MECP2
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
RU2017137410A
(ru)
|
2015-04-03 |
2019-05-06 |
Ионис Фармасьютикалз, Инк. |
Соединения и способы модулирования экспрессии tmprss6
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
SG11201708468YA
(en)
|
2015-04-16 |
2017-11-29 |
Ionis Pharmaceuticals Inc |
Compositions for modulating c9orf72 expression
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
EP4365291A2
(en)
|
2015-06-12 |
2024-05-08 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
US20180188257A1
(en)
|
2015-06-19 |
2018-07-05 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
EP3313989A4
(en)
|
2015-06-29 |
2018-12-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
PE20180800A1
(es)
|
2015-07-10 |
2018-05-09 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
WO2017024111A1
(en)
|
2015-08-04 |
2017-02-09 |
The University Of Chicago |
Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
|
CN107922945A
(zh)
|
2015-08-24 |
2018-04-17 |
罗氏创新中心哥本哈根有限公司 |
Lna‑g 方法
|
CN108368507B
(zh)
|
2015-09-02 |
2022-03-22 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
PT3349802T
(pt)
|
2015-09-14 |
2021-10-15 |
Univ Texas |
Dendrímeros lipocatiónicos e suas utilizações
|
TW201723176A
(zh)
|
2015-09-24 |
2017-07-01 |
Ionis製藥公司 |
Kras表現之調節劑
|
JP6853539B2
(ja)
|
2015-09-24 |
2021-03-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
EP3960183A1
(en)
|
2015-10-08 |
2022-03-02 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
US11078528B2
(en)
|
2015-10-12 |
2021-08-03 |
Advanced Cell Diagnostics, Inc. |
In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
WO2017079291A1
(en)
|
2015-11-02 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating c90rf72
|
US20190046555A1
(en)
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
WO2017079739A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
MODULATING APOLIPOPROTEIN (a) EXPRESSION
|
CN116064540A
(zh)
|
2015-11-12 |
2023-05-05 |
豪夫迈·罗氏有限公司 |
用于诱导父本ube3a表达的寡核苷酸
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
WO2017106377A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
JPWO2017111137A1
(ja)
*
|
2015-12-22 |
2018-10-18 |
味の素株式会社 |
オリゴヌクレオチドの製造方法
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
EP4015647B1
(en)
|
2016-02-26 |
2023-08-30 |
The Board of Trustees of the Leland Stanford Junior University |
Multiplexed single molecule rna visualization with a two-probe proximity ligation system
|
US11364258B2
(en)
|
2016-03-04 |
2022-06-21 |
Rhode Island Hospital |
Methods for treating chondrosarcoma using microrna(miR)
|
WO2017156242A1
(en)
|
2016-03-09 |
2017-09-14 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting pmp22 expression
|
AU2017235278C1
(en)
|
2016-03-14 |
2022-03-10 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for reduction of PD-L1 expression
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
EP3429690A4
(en)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR MODULATING KEAP1
|
WO2017157672A1
(en)
|
2016-03-18 |
2017-09-21 |
Roche Innovation Center Copenhagen A/S |
Acyl-protected l-lna-guanosine monomers
|
AU2017248637A1
(en)
|
2016-04-13 |
2018-09-27 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing C9ORF72 expression
|
CN109153697A
(zh)
|
2016-04-14 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
三苯甲基-单-GalNAc化合物及其用途
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
EP3455232B1
(en)
|
2016-05-12 |
2020-05-06 |
Roche Innovation Center Copenhagen A/S |
Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
|
BR112018073699A2
(pt)
|
2016-05-16 |
2019-05-07 |
The Board Of Regents Of The University Of Texas System |
amino lipídios de sulfonamida catiônica e amino lipídios zwiteriônico anfifílicos
|
JP6876383B2
(ja)
*
|
2016-06-07 |
2021-05-26 |
富士通オプティカルコンポーネンツ株式会社 |
波長可変光源
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
AU2017284202B2
(en)
|
2016-06-14 |
2021-11-04 |
Biogen Ma Inc. |
Hydrophobic interaction chromatography for purification of oligonucleotides
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
EP3471781A4
(en)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
MODULATING THE GYS1 EXPRESSION
|
JP7012033B2
(ja)
|
2016-06-17 |
2022-02-10 |
エフ.ホフマン-ラ ロシュ アーゲー |
インビトロ腎毒性スクリーニングアッセイ
|
JP7049271B2
(ja)
|
2016-06-17 |
2022-04-06 |
エフ.ホフマン-ラ ロシュ アーゲー |
インビトロ腎毒性スクリーニングアッセイ
|
HUE060123T2
(hu)
|
2016-06-24 |
2023-01-28 |
Scripps Research Inst |
Új nukleozid-trifoszfát-transzporter és alkalmazásai
|
CA3026855A1
(en)
|
2016-07-01 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
EP3481430A4
(en)
|
2016-07-11 |
2020-04-01 |
Translate Bio Ma, Inc. |
NUCLEIC ACID CONJUGATES AND USES THEREOF
|
JP7197463B2
(ja)
|
2016-07-15 |
2022-12-27 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Smn2の調節のための化合物及び方法
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
WO2018067546A1
(en)
|
2016-10-03 |
2018-04-12 |
President And Fellows Of Harvard College |
Delivery of therapeutic rnas via arrdc1-mediated microvesicles
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
JP7033591B2
(ja)
|
2016-11-11 |
2022-03-10 |
ロシュ イノベーション センター コペンハーゲン エーエス |
治療用オリゴヌクレオチドの捕捉および検出
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
EP3548620A4
(en)
|
2016-12-02 |
2020-07-22 |
Cold Spring Harbor Laboratory |
MODULATION OF THE EXPRESSION OF LNC05
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
EP3568477A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
EP3568478A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
JP7164540B2
(ja)
|
2017-03-29 |
2022-11-01 |
ロシュ イノベーション センター コペンハーゲン エーエス |
立体的に規定されたホスホロチオエートオリゴヌクレオチドの調製のための直交保護基
|
CA3059446A1
(en)
|
2017-04-18 |
2018-10-25 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
EP3599844A4
(en)
|
2017-06-07 |
2021-01-13 |
University of Massachusetts |
ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED PROCESSES
|
US11814407B2
(en)
|
2017-06-28 |
2023-11-14 |
Roche Innovation Center Copenhagen A/S |
Multiple coupling and oxidation method
|
AU2018300069A1
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法
|
US20200181220A1
(en)
|
2017-08-03 |
2020-06-11 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
SG10202108375XA
(en)
|
2017-08-25 |
2021-09-29 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
WO2019073018A1
(en)
|
2017-10-13 |
2019-04-18 |
Roche Innovation Center Copenhagen A/S |
METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
|
CN111511914B
(zh)
|
2017-10-16 |
2023-11-17 |
豪夫迈·罗氏有限公司 |
减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
|
US11866701B2
(en)
|
2017-11-01 |
2024-01-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
JP2021506239A
(ja)
|
2017-12-14 |
2021-02-22 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
複合アンチセンス化合物及びその使用
|
EP3728593A1
(en)
|
2017-12-18 |
2020-10-28 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
AU2018390167A1
(en)
|
2017-12-21 |
2020-06-11 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for HTRA1 RNA antagonists
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
AU2018386527A1
(en)
|
2017-12-22 |
2020-04-30 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
KR20200104302A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
신규 티오포스포르아미다이트
|
EP4074724A1
(en)
|
2017-12-22 |
2022-10-19 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
US20210095274A1
(en)
|
2018-01-10 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
WO2019140236A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
AU2019208006A1
(en)
|
2018-01-12 |
2020-07-23 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
CA3085964A1
(en)
|
2018-01-12 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
MA51645A
(fr)
|
2018-01-15 |
2020-11-25 |
Ionis Pharmaceuticals Inc |
Modulateurs de l'expression de dnm2
|
US20210095276A1
(en)
|
2018-01-17 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Srebp1を標的とするアンチセンスオリゴヌクレオチド
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
SG11202007093YA
(en)
|
2018-02-09 |
2020-08-28 |
Genentech Inc |
Oligonucleotides for modulating tmem106b expression
|
AU2019218987A1
(en)
|
2018-02-12 |
2020-07-23 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
EP3755800A1
(en)
|
2018-02-21 |
2020-12-30 |
Bristol-Myers Squibb Company |
Camk2d antisense oligonucleotides and uses thereof
|
CN112004547A
(zh)
|
2018-02-26 |
2020-11-27 |
新索思股份有限公司 |
Il-15缀合物及其用途
|
US11241451B2
(en)
|
2018-03-02 |
2022-02-08 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF4 expression
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
AU2019237599A1
(en)
|
2018-03-20 |
2020-11-12 |
Nissan Chemical Corporation |
Antisense oligonucleotide having reduced toxicity
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
AU2019247645A1
(en)
|
2018-04-05 |
2020-10-15 |
Centre Leon Berard |
Use of FUBP1 inhibitors for treating hepatitis B virus infection
|
US11788124B2
(en)
|
2018-04-09 |
2023-10-17 |
Advanced Cell Diagnostics, Inc. |
Methods to further enhance signal amplification for the in situ detection of nucleic acids
|
KR20200141481A
(ko)
|
2018-04-11 |
2020-12-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ezh2 발현의 조절제
|
JP2021522816A
(ja)
|
2018-05-07 |
2021-09-02 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチド治療のための超並列的探索方法
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
AU2019266307A1
(en)
|
2018-05-09 |
2020-11-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN3 expression
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
WO2019219723A1
(en)
|
2018-05-18 |
2019-11-21 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions for treatment of microrna related diseases
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
US11066669B2
(en)
|
2018-06-05 |
2021-07-20 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
JP2021526823A
(ja)
|
2018-06-14 |
2021-10-11 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Stmn2発現を増加させるための化合物及び方法
|
CN112400019B
(zh)
|
2018-06-27 |
2024-05-07 |
Ionis制药公司 |
用于减少lrrk2表达的化合物和方法
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
CR20210058A
(es)
|
2018-07-03 |
2021-03-22 |
Hoffmann La Roche |
Oligonucleótidos para modular la expresión de tau
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
AU2019300324A1
(en)
|
2018-07-13 |
2021-01-21 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating RTEL1 expression
|
AR115847A1
(es)
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de la atxn2
|
WO2020025563A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
BR112020025272A2
(pt)
|
2018-07-31 |
2021-03-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
|
MX2021001056A
(es)
|
2018-08-13 |
2021-04-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
|
BR112021002779A2
(pt)
|
2018-08-15 |
2021-05-04 |
Illumina, Inc. |
composições e métodos para melhorar o enriquecimento de bibliotecas
|
EP3837367A1
(en)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
AU2019325255A1
(en)
|
2018-08-20 |
2021-04-15 |
Rogcon, Inc. |
Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
|
EP3841220A1
(en)
|
2018-08-23 |
2021-06-30 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
CN113728102A
(zh)
|
2018-08-28 |
2021-11-30 |
罗氏创新中心哥本哈根有限公司 |
使用剪接调节化合物进行新抗原工程化
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
EP3620520A1
(en)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Novel target to treat a metabolic disease in an individual
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ.ホフマン-ラ ロシュ アーゲー |
Tia1を標的とするアンチセンスオリゴヌクレオチド
|
WO2020097342A1
(en)
*
|
2018-11-08 |
2020-05-14 |
Aligos Therapeutics, Inc. |
S-antigen transport inhibiting oligonucleotide polymers and methods
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
JOP20210108A1
(ar)
|
2018-11-15 |
2023-01-30 |
Ionis Pharmaceuticals Inc |
معدِّلات تعبير irf5
|
KR20210093970A
(ko)
|
2018-11-21 |
2021-07-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
프리온 발현을 감소시키기 위한 화합물 및 방법
|
CN113166185A
(zh)
|
2018-11-22 |
2021-07-23 |
罗氏创新中心哥本哈根有限公司 |
作为立体限定的寡核苷酸合成中的活化剂的吡啶鎓盐
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
HRP20231338T1
(hr)
|
2018-12-20 |
2024-02-16 |
Vir Biotechnology, Inc. |
Kombinirana terapija hbv
|
US20220056455A1
(en)
|
2018-12-20 |
2022-02-24 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
CN113330118A
(zh)
|
2018-12-21 |
2021-08-31 |
勃林格殷格翰国际有限公司 |
靶向card9的反义寡核苷酸
|
WO2020150431A1
(en)
|
2019-01-16 |
2020-07-23 |
Genzyme Corporation |
Serpinc1 irna compositions and methods of use thereof
|
EP3914232A1
(en)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
AU2020216444A1
(en)
|
2019-01-31 |
2021-07-29 |
Ionis Pharmaceuticals, Inc. |
Modulators of YAP1 expression
|
CN114949240A
(zh)
|
2019-02-06 |
2022-08-30 |
新索思股份有限公司 |
Il-2缀合物及其使用方法
|
EP3924501A4
(en)
|
2019-02-15 |
2022-11-23 |
Advanced Cell Diagnostics, Inc. |
METHODS FOR MULTIPLEX DETECTION OF NUCLEIC ACIDS BY IN SITU HYBRIDIZATION
|
MX2021009950A
(es)
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros de fosfonoacetato.
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
EP3931348B1
(en)
|
2019-02-26 |
2023-08-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
EP3931328A4
(en)
|
2019-02-27 |
2023-09-13 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF MALAT1 EXPRESSION
|
WO2020178258A1
(en)
|
2019-03-05 |
2020-09-10 |
F. Hoffmann-La Roche Ag |
Intracellular targeting of molecules
|
CN113747925A
(zh)
|
2019-03-21 |
2021-12-03 |
科迪亚克生物科学公司 |
胞外囊泡缀合物及其用途
|
WO2020191177A1
(en)
|
2019-03-21 |
2020-09-24 |
Sudhir Agrawal |
Antisense oligonucleotides for allele specificity
|
PE20220284A1
(es)
|
2019-03-29 |
2022-02-25 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular ube3a-ats
|
CA3198029A1
(en)
|
2019-03-29 |
2020-10-08 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for modulating expression of dux4
|
SG11202110745VA
(en)
|
2019-04-03 |
2021-10-28 |
Bristol Myers Squibb Co |
Angptl2 antisense oligonucleotides and uses thereof
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
EP3947677A1
(en)
|
2019-04-04 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
CN113661168A
(zh)
|
2019-04-16 |
2021-11-16 |
罗氏创新中心哥本哈根有限公司 |
用于制备核苷酸p(v)单体的新方法
|
EP3962918A1
(en)
|
2019-04-30 |
2022-03-09 |
Roche Innovation Center Copenhagen A/S |
Novel process for preparing rhenium chelated mag3 oligonucleotides
|
CN113795581A
(zh)
|
2019-05-03 |
2021-12-14 |
迪克纳制药公司 |
具有缩短的有义链的双链核酸抑制剂分子
|
WO2020227395A2
(en)
|
2019-05-06 |
2020-11-12 |
University Of Massachusetts |
Anti-c9orf72 oligonucleotides and related methods
|
MX2021013698A
(es)
|
2019-05-13 |
2021-12-10 |
Vir Biotechnology Inc |
Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb).
|
TW202111123A
(zh)
|
2019-05-28 |
2021-03-16 |
美商Ionis製藥公司 |
用於減少fus 表現之化合物及方法
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
AU2020291535A1
(en)
|
2019-06-14 |
2022-01-20 |
The Scripps Research Institute |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATION OF GFAP
|
EP4007811A2
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
CN114641570A
(zh)
|
2019-08-14 |
2022-06-17 |
科迪亚克生物科学公司 |
具有靶向kras的反义寡核苷酸的细胞外囊泡
|
CA3147366A1
(en)
|
2019-08-14 |
2021-02-18 |
Adam T. BOUTIN |
Extracellular vesicles with stat3-antisense oligonucleotides
|
WO2021030773A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
CA3147369A1
(en)
|
2019-08-14 |
2021-02-18 |
Dalia BURZYN |
Extracellular vesicle-aso constructs targeting cebp/beta
|
CA3147680A1
(en)
|
2019-08-14 |
2021-02-18 |
Dalia BURZYN |
Extracellular vesicle-aso constructs targeting stat6
|
EP4013457A1
(en)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extracellular vesicle linked to molecules and uses thereof
|
TW202120128A
(zh)
|
2019-08-15 |
2021-06-01 |
美商欣爍克斯公司 |
使用il-2接合物之免疫腫瘤學組合療法
|
WO2021030778A1
(en)
|
2019-08-15 |
2021-02-18 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
TW202122401A
(zh)
|
2019-08-23 |
2021-06-16 |
美商欣爍克斯公司 |
新穎之il-15接合物及其用途
|
CN114616331A
(zh)
|
2019-09-03 |
2022-06-10 |
阿尔尼拉姆医药品有限公司 |
抑制lect2基因表达的组合物和方法
|
JP2022547078A
(ja)
|
2019-09-10 |
2022-11-10 |
シンソークス, インコーポレイテッド |
Il-2コンジュゲートおよび自己免疫疾患を治療するための使用方法
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
WO2021081026A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
EP4051795A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
JP2022554272A
(ja)
|
2019-11-04 |
2022-12-28 |
シンソークス, インコーポレイテッド |
インターロイキン10コンジュゲートおよびその使用
|
JP2023502038A
(ja)
|
2019-11-13 |
2023-01-20 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アンギオテンシノーゲン(agt)関連障害を処置するための方法および組成物
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
BR112022011417A2
(pt)
|
2019-12-13 |
2022-08-30 |
Alnylam Pharmaceuticals Inc |
Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
|
WO2021122869A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of scamp3 inhibitors for treating hepatitis b virus infection
|
CN114829601A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
|
CN114901821A
(zh)
|
2019-12-19 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
|
CN115516091A
(zh)
|
2019-12-19 |
2022-12-23 |
豪夫迈·罗氏有限公司 |
Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
|
CN114867856A
(zh)
|
2019-12-19 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
|
WO2021123086A1
(en)
|
2019-12-20 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Enhanced oligonucleotides for inhibiting scn9a expression
|
JP2023509872A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
JP2023514336A
(ja)
|
2020-02-18 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用法
|
EP4110916A1
(en)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating cd73 exon 7 splicing
|
KR20220148230A
(ko)
|
2020-02-28 |
2022-11-04 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Smn2를 조절하기 위한 화합물 및 방법
|
CN116096420A
(zh)
|
2020-03-02 |
2023-05-09 |
田边三菱制药株式会社 |
利用miR-33b抑制物质的动脉瘤的预防或治疗
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
AU2021232029A1
(en)
|
2020-03-06 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin (TTR)
|
JP2023516095A
(ja)
|
2020-03-06 |
2023-04-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
EP4127168A1
(en)
|
2020-03-26 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
KR20230008729A
(ko)
|
2020-04-06 |
2023-01-16 |
알닐람 파마슈티칼스 인코포레이티드 |
Myoc 발현을 사일런싱하기 위한 조성물 및 방법
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
WO2021207189A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
IL297680A
(en)
|
2020-04-30 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
IRNA compounds complement factor b (cfb) and methods of using them
|
WO2021222768A2
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
JP2023527684A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック, インコーポレイテッド |
神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法
|
US20230287410A1
(en)
|
2020-05-11 |
2023-09-14 |
Stoke Therapeutics, Inc. |
Opa1 antisense oligomers for treatment of conditions and diseases
|
EP4150085A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
EP4150084A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
JPWO2021230286A1
(US07399845-20080715-C00049.png)
|
2020-05-12 |
2021-11-18 |
|
|
JP2023526267A
(ja)
|
2020-05-13 |
2023-06-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
プログラニュリン標的オリゴヌクレオチドアゴニスト
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
JP2023526096A
(ja)
|
2020-05-22 |
2023-06-20 |
エフ. ホフマン-ラ ロシュ アーゲー |
Card9のスプライス調節のためのオリゴヌクレオチド
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
CN115702243A
(zh)
|
2020-06-09 |
2023-02-14 |
罗氏创新中心哥本哈根有限公司 |
用于治疗性多核苷酸的鸟苷类似物
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
EP4168546A1
(en)
|
2020-06-18 |
2023-04-26 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
KR20230042023A
(ko)
|
2020-06-24 |
2023-03-27 |
비르 바이오테크놀로지, 인코포레이티드 |
조작된 b형 간염 바이러스 중화 항체 및 이의 용도
|
IL299074A
(en)
|
2020-06-25 |
2023-02-01 |
Synthorx Inc |
Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
WO2022006134A2
(en)
|
2020-06-29 |
2022-01-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating plp1
|
US20230272386A1
(en)
|
2020-07-17 |
2023-08-31 |
Mitsubishi Tanabe Pharma Corporation |
Agent for preventing or treating muscular disease
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
EP4185696A1
(en)
|
2020-07-23 |
2023-05-31 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting rna binding protein sites
|
CN116157522A
(zh)
|
2020-08-21 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
WO2022076859A1
(en)
|
2020-10-09 |
2022-04-14 |
Synthorx, Inc. |
Immuno oncology therapies with il-2 conjugates
|
BR112023006364A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
|
EP4232581A1
(en)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
MX2023005490A
(es)
|
2020-11-13 |
2023-05-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) del factor de coagulacion v (f5) y sus metodos de uso.
|
EP4247950A1
(en)
|
2020-11-18 |
2023-09-27 |
Lemba BV |
Umlilo antisense transcription inhibitors
|
KR20230108728A
(ko)
|
2020-11-18 |
2023-07-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
|
CA3202708A1
(en)
|
2020-11-23 |
2022-05-27 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
WO2022117747A2
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
WO2022122613A1
(en)
|
2020-12-08 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Novel synthesis of phosphorodithioate oligonucleotides
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
JP2023553710A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ. ホフマン-ラ ロシュ アーゲー |
Xbp1を標的とするオリゴヌクレオチド
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
EP4291243A1
(en)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
TW202245843A
(zh)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
IL305171A
(en)
|
2021-02-17 |
2023-10-01 |
Lonza Sales Ag |
EXTRACELLULAR VESILE-NLRP3 antagonist
|
WO2022178180A1
(en)
|
2021-02-17 |
2022-08-25 |
Codiak Biosciences, Inc. |
Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
AU2022226098A1
(en)
|
2021-02-26 |
2023-08-24 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2022187435A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
BR112023019981A2
(pt)
|
2021-03-29 |
2023-12-12 |
Alnylam Pharmaceuticals Inc |
Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
|
IL307298A
(en)
|
2021-03-31 |
2023-11-01 |
Entrada Therapeutics Inc |
Cell-penetrating circular peptides
|
CA3213989A1
(en)
|
2021-04-01 |
2022-10-06 |
Conlin O'NEIL |
Extracellular vesicle compositions
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
TW202309291A
(zh)
|
2021-04-07 |
2023-03-01 |
法商新植物Sas公司 |
用於室內空氣修復之組合物及方法
|
BR112023022284A2
(pt)
|
2021-04-26 |
2023-12-26 |
Alnylam Pharmaceuticals Inc |
Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
JPWO2022230987A1
(US07399845-20080715-C00049.png)
|
2021-04-30 |
2022-11-03 |
|
|
JP2024518068A
(ja)
|
2021-05-10 |
2024-04-24 |
エントラーダ セラピューティクス,インコーポレイティド |
細胞内治療のための組成物及び方法
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
EP4337261A2
(en)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating mrna splicing
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
AU2022285661A1
(en)
|
2021-05-29 |
2023-12-21 |
1Globe Health Institute Llc |
Asymmetric short duplex dna as a novel gene silencing technology and use thereof
|
WO2022256354A1
(en)
|
2021-05-29 |
2022-12-08 |
1Globe Health Institute Llc |
Short duplex dna as a novel gene silencing technology and use thereof
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP4346904A1
(en)
|
2021-06-03 |
2024-04-10 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
EP4347822A2
(en)
|
2021-06-04 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
AU2022288115A1
(en)
|
2021-06-08 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
EP4105328A1
(en)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
|
CA3223192A1
(en)
|
2021-06-18 |
2022-12-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
KR20240038967A
(ko)
|
2021-06-23 |
2024-03-26 |
엔트라다 테라퓨틱스, 인크. |
Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2023278576A1
(en)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
IL309905A
(en)
|
2021-07-23 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions in β-catenin (CTNNB1) and methods of using them
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
KR20240042004A
(ko)
|
2021-08-03 |
2024-04-01 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물 및 이의 사용 방법
|
AU2022324003A1
(en)
|
2021-08-04 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
KR20240045300A
(ko)
|
2021-08-13 |
2024-04-05 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 XII (F12) iRNA 조성물 및 이의 사용 방법
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
AU2022339769A1
(en)
|
2021-09-01 |
2024-03-28 |
Entrada Therapeutics, Inc. |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
AR127158A1
(es)
|
2021-09-29 |
2023-12-27 |
Hoffmann La Roche |
Oligonucléotido antisentido para la edición de arn asociado a enfermedades de poliglutamina
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
WO2023083906A2
(en)
|
2021-11-11 |
2023-05-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023127857A1
(ja)
*
|
2021-12-27 |
2023-07-06 |
株式会社理研ジェネシス |
新規人工核酸、その製造方法及び用途
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023156652A1
(en)
|
2022-02-21 |
2023-08-24 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotide
|
WO2023178144A2
(en)
|
2022-03-16 |
2023-09-21 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
WO2023222858A1
(en)
|
2022-05-18 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Improved oligonucleotides targeting rna binding protein sites
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|